Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Impact of Hispanic ethnicity on immunotherapy outcomes in hepatocellular carcinoma: Insights from the National Cancer Database.
Authors
Sumit Gaur
Texas Tech University Health Science Center, El Paso, TX
Sumit Gaur , Alok Kumar Dwivedi , Ana Eiring , Ioannis Konstantinidis , Rabia Rukhsan , Vishwajeet Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Cancer Disparities
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 438)
DOI
10.1200/JCO.2024.42.3_suppl.438
Abstract #
438
Poster Bd #
A3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Evaluating racial disparities for patients with advanced hepatocellular carcinoma (HCC) receiving first line immunotherapy within an equal access system.
First Author: Lauren Diaz Boyle
First Author: Chi Leung Chiang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II clinical trial to study the use of cabozantinib (cabo) in patients with hepatocellular carcinoma (HCC) post immunotherapy treatment.
First Author: Stephen Lam Chan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
First Author: Chloe Lim